126.59 0.00 (0.00%)
After hours: 6:10PM EDT
|Bid||124.00 x 800|
|Ask||130.00 x 900|
|Day's range||126.26 - 129.00|
|52-week range||78.90 - 130.09|
|Beta (3Y monthly)||0.61|
|PE ratio (TTM)||44.73|
|Earnings date||7 Nov 2019|
|Forward dividend & yield||0.66 (0.51%)|
|1y target est||136.00|
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and commercializes medicines, vaccines and diagnostic products, which are complemented by biodevices, genetic tests and a range of services. Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events.
Zoetis Inc. (ZTS) today announced that Kristin Peck will succeed Juan Ramón Alaix as Chief Executive Officer, effective January 1, 2020, and join the Board of Directors, effective immediately. Alaix, who has been CEO of Zoetis since its formation in 2012, has decided to retire as CEO effective December 31, 2019.
Simparica Trio™, a Once-Monthly Triple Combination Antiparasitic Medication for Dogs, receives Notice of Compliance from Health Canada's Veterinary Drugs Directorate
Zoetis Inc. will host a webcast and conference call at 8:30 a.m. on Thursday, Nov. 7, 2019. Chief Executive Officer Juan Ramón Alaix and Executive Vice President and Chief Financial Officer Glenn David will review third quarter 2019 financial results and respond to questions from financial analysts during the call.
Zoetis Inc. (ZTS) today announced that the European Commission has granted marketing authorisation for Simparica Trio™ (sarolaner/moxidectin/pyrantel) chewable tablets, a once-monthly triple combination antiparasitic medication for dogs with, or at risk from, mixed external and internal parasitic infestations. The granting of the marketing authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Veterinary Use on July 18, 2019.
Lescault, 43, who enrolled Moose in a clinical trial of an experimental drug designed to help his immune system fight his cancer, represents the type of pet lover that has spurred animal health companies around the globe to invest in developing complex new treatments previously reserved for humans. Biotechnology, which produces medicines from living cells, revolutionized the drug industry more than a quarter century ago with breakthrough medicines at prices that now run as high as hundreds of thousands of dollars a year.
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Triple combination product contains sarolaner, moxidectin and pyrantel